Harbin Gloria Pharmaceuticals (002437) — Working Capital to Net Assets Ratio
Harbin Gloria Pharmaceuticals (002437) has a Working Capital to Net Assets ratio of 26.6% as of March 2026. Working capital of CN¥639.55 Million (current assets of CN¥1.35 Billion minus current liabilities of CN¥709.56 Million) is measured against net assets of CN¥2.41 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See 002437 net asset quality score to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Harbin Gloria Pharmaceuticals Working Capital to Net Assets (2007–2025)
This chart shows how Harbin Gloria Pharmaceuticals's Working Capital to Net Assets ratio has evolved across 19 annual periods from 2007 to 2025. As of March 2026, the ratio stands at 26.6%, reflecting working capital of CN¥639.55 Million against net assets of CN¥2.41 Billion CNY. Check 002437 tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Harbin Gloria Pharmaceuticals (2007–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Harbin Gloria Pharmaceuticals from 2007 to 2025, covering 19 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see 002437 company net worth.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 22.6% | CN¥521.00 Million | CN¥2.31 Billion | CN¥1.32 Billion | CN¥797.85 Million | ▲ +19.8 pp |
| 2024 | 2.7% | CN¥54.16 Million | CN¥1.97 Billion | CN¥877.19 Million | CN¥823.03 Million | ▲ +17.8 pp |
| 2023 | -15.1% | CN¥-257.78 Million | CN¥1.71 Billion | CN¥1.15 Billion | CN¥1.41 Billion | ▲ +15.5 pp |
| 2022 | -30.5% | CN¥-520.11 Million | CN¥1.70 Billion | CN¥1.82 Billion | CN¥2.34 Billion | ▼ -6.4 pp |
| 2021 | -24.1% | CN¥-477.90 Million | CN¥1.98 Billion | CN¥2.20 Billion | CN¥2.68 Billion | ▲ +14.9 pp |
| 2020 | -39.1% | CN¥-755.39 Million | CN¥1.93 Billion | CN¥1.79 Billion | CN¥2.54 Billion | ▲ +59.3 pp |
| 2019 | -98.4% | CN¥-1.56 Billion | CN¥1.59 Billion | CN¥3.20 Billion | CN¥4.77 Billion | ▼ -71.0 pp |
| 2018 | -27.3% | CN¥-1.20 Billion | CN¥4.39 Billion | CN¥2.82 Billion | CN¥4.02 Billion | ▲ +1.9 pp |
| 2017 | -29.2% | CN¥-1.24 Billion | CN¥4.25 Billion | CN¥2.03 Billion | CN¥3.27 Billion | ▲ +8.0 pp |
| 2016 | -37.3% | CN¥-1.51 Billion | CN¥4.05 Billion | CN¥2.01 Billion | CN¥3.52 Billion | ▲ +18.6 pp |
| 2015 | -55.8% | CN¥-1.94 Billion | CN¥3.47 Billion | CN¥2.06 Billion | CN¥4.00 Billion | ▼ -58.9 pp |
| 2014 | 3.1% | CN¥94.99 Million | CN¥3.10 Billion | CN¥1.53 Billion | CN¥1.44 Billion | ▼ -40.6 pp |
| 2013 | 43.6% | CN¥1.08 Billion | CN¥2.48 Billion | CN¥1.53 Billion | CN¥446.25 Million | ▼ -29.2 pp |
| 2012 | 72.9% | CN¥1.72 Billion | CN¥2.36 Billion | CN¥1.91 Billion | CN¥186.79 Million | ▼ -6.2 pp |
| 2011 | 79.1% | CN¥1.74 Billion | CN¥2.20 Billion | CN¥1.82 Billion | CN¥81.27 Million | ▼ -4.0 pp |
| 2010 | 83.1% | CN¥1.76 Billion | CN¥2.12 Billion | CN¥1.84 Billion | CN¥73.73 Million | ▲ +56.5 pp |
| 2009 | 26.6% | CN¥76.45 Million | CN¥287.53 Million | CN¥231.40 Million | CN¥154.95 Million | ▼ -14.5 pp |
| 2008 | 41.1% | CN¥79.83 Million | CN¥194.04 Million | CN¥164.71 Million | CN¥84.89 Million | ▲ +14.4 pp |
| 2007 | 26.7% | CN¥36.95 Million | CN¥138.36 Million | CN¥112.73 Million | CN¥75.79 Million | — |